Compelling Tegoprubart Data in Type 1 Diabetes Transplantation Support Buy Rating on Eledon

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals, with a price target of $4.00.

Rami Katkhuda has given his Buy rating due to a combination of factors, foremost among them the compelling clinical profile of tegoprubart in islet cell transplantation for long‑standing Type 1 diabetes. The updated University of Chicago data show rapid and durable insulin independence in nearly all evaluable patients, with hemoglobin A1c levels falling well below typical treatment targets, which supports the drug’s potential to meaningfully improve disease control.

Equally important to his view is the favorable safety and tolerability profile, as tegoprubart appears to avoid key toxicities commonly linked to tacrolimus while maintaining graft function without rejection or donor‑specific antibodies. When combined with a near‑term regulatory update anticipated in 2026 and the broader applicability of tegoprubart across transplantation settings, these data underpin a constructive risk‑reward outlook that supports a Buy recommendation on Eledon shares.

Katkhuda covers the Healthcare sector, focusing on stocks such as Disc Medicine, Viridian Therapeutics, and MoonLake Immunotherapeutics. According to TipRanks, Katkhuda has an average return of 32.0% and a 53.85% success rate on recommended stocks.